Newsletters

[PCF] The Prostate Cancer Foundation (PCF) announced $6.3 million in funding for 31 exceptional Young Investigators pursuing groundbreaking discoveries in prostate cancer.

[Candel Therapeutics, Inc.] Candel Therapeutics, Inc. announced a $100 million royalty funding agreement with funds managed by RTW Investments, subject to FDA approval of aglatimagene in intermediate- to high-risk, localized prostate cancer.

[Acta Pharmacologica Sinica] Using integrating bioinformatics analysis and proteomic research, scientists identified 12 differentially expressed proteins in NDGA-treated prostate cancer cells that were associated with EZH2, a histone methyltransferase and a catalytic component of polycomb repressive complex 2 (PRC2).

[Nature Reviews Urology] Emerging evidence demonstrates that current androgen deprivation therapy (ADT) induces HGF and canonical WNT signalling activation, which further elevates nuclear exporting and ribosomal biogenesis to foster tumour lineage plasticity and promote diverse CRPC phenotypes and double-null prostate cancer development.

[Cell Communication and Signaling] Investigators explored the anti-cancer effects and mechanisms of action of trichodermamide B in targeting catalase-induced apoptosis in prostate cancer cells.

[Cancer Gene Therapy] FOSB is downregulated in prostate cancer (PCa), and its high expression in tumours may reduce the risk of PCa progression by influencing characteristic growth-related cancer pathways.

[Oncogene] Knockdown of YEATS domain-containing 2 (YEATS2) reduced the metastatic potential of prostate cancer cells both in vivo and in vitro, whereas its overexpression inhibited anoikis and promoted metastasis by upregulating the expression of the DNA damage repair gene RAD50.

[Scientific Reports] Researchers evaluated the impact of miR-340-mediated downregulation of MDM2 on the therapeutic efficacy of p53 gene therapy in p53 non-expressing prostate cancer cells.

[Everest Medicines] Everest Medicines announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY^® for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

[Cell Discovery] Researchers identified palmitic acid as a metabolite cue that activates c-Myc via dual palmitoylation-dependent pathways operating across tumor initiation and progression.

[Gut] Investigators elucidated the role of Acinetobacter baumannii in enhancing nicotinamide adenine dinucleotide (NAD) metabolism in gastric cancer (GC) cells through NA synthesis, consequently promoting GC metastasis.

[Gut] Scientists aimed to develop mouse models of sporadic and hereditary diffuse gastric cancer (DGC) by inactivation of Cdh1 in the mouse stomach. They generated tamoxifen-inducible Cre/loxP mouse models of DGC driven by the Cd44 promoter with a tdTomato reporter.